BPT 143
Alternative Names: BPT-143Latest Information Update: 28 May 2024
Price :
$50 *
At a glance
- Originator Bright Peak Therapeutics
- Class Antineoplastics; Immunotherapies; Interleukins; Recombinant proteins
- Mechanism of Action Immunostimulants; Interleukin 2 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2024 No recent reports of development identified for preclinical development in Cancer in Switzerland
- 08 Apr 2022 Pharmacodynamics, pharmacokinetics and adverse events data from preclinical trial presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
- 17 Jun 2021 Preclinical trials in Cancer in Switzerland